Welcome to the George-Huntington-Institute
The George-Huntington-Institute (GHI) located in Muenster/Germany is devoted to clinical care and preclinical and clinical research in Huntington's disease (HD). GHI entertains one of the largest HD out-patient clinics for sympotmatic and premanifest gene carriers, persons at-risk and caregivers around the world. GHI offers participation in ENROLL-HD, HD-Clarity and multiple clinical trials aimed at improving therapeutic options for HD.
Are you affected by Huntingtons Disease and have questions about it?
To contact us or to ask for an appointment please call: +49-251-788-788-0, send us an email to info (at) ghi-muenster.de. Emergency appointments can be accomodated. We look forward to hearing from you!
First information about Huntington's disease in German is available in a booklet entitled "Huntington's disease compact" providing treatment options and frequently asekd questions for patients and caregivers in lay language. It was publihed by Thieme in 2022 and edited by Drs. Ralf Reilmann and Bernhard Landwehrmeyer.
The booklet is available online at no charge if you click on the picture on the right:
News
PROOF-HD Update
Eine genauere Auswertung der PROOF-HD Studie hat gezeigt, dass Patienten von Pridopidine profitieren, wenn sie gewisse Medikament nicht einnehmen. Die Firma Prilenia hat daher bei der europäischen Zulassungsbehörde EMA beantragt, das Medikament für Huntington Patienten zuzulassen. Die EMA wird sich die Daten nun anschauen und dann mit einer Beurteilung der Sachlage an den Sponsor herantreten. Es ist also möglich, dass Pridopidine eine Zulassung in Europa bekommt. Ob es wirklich dazu kommt bleibt aber abzuwarten.
Read more
ALNYLAM-Study
GHI will offer the Alnylam Study ALN-HTT02-001 shortly. More details to follow.
Read more
SOM-Biotech Study completed
GHI participates in a study sponsorded by SOM-Biotech that investigates a new drug aiming to redcue chora in Huntington's disease.
Read more
PIVOT-HD study sponsored by PTC THerapeutics recruits at GHI
The "PIVOT-HD" study sponsored by PTC Therapeutics investigates an oral drug aiming to lower the production of the protein huntingtin.
Read more
SELECT-HD ASO study sponsored by WAVE recrutis at GHI
"SELECT-HD" aims to selectively reduce production of the mutated huntingtin using an ASO.
Read more
Roche Studie Generation-HD1 stoppt weitere Dosierung
Die Firma Roche hat in einer Pressemeldung mitgeteilt, dass die Generation-HD1 Studie mit dem Antise...
Read moreAbout Us
Our Team
We're a multidisciplinary team of neurologists, physicians, study nurses and natural scientists, to provide clinical care and advance clinical research in HD.
Read morePresent clinical studies and projects
Contact us if you are interested in clinical studies that are currently conducted. GHI participates in most of the clinical trials that are conducted in HD globally.
Read moreLooking for a job in HD research?
Are you interested in helping out to find a cure for HD? Or do you want to help our team with the clinical care of HD patients? Find our job openings here.
Read more